Integromic analysis of the NCI-60 cancer cell lines

Breast Disease

Volumn 19, Issue , 2004, Pages 11-22

  Weinstein, John N ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bioinformatics; Cancer; Cell line; Genomic; Microarray; National Cancer Institute; NCI 60 cell lines; Pharmacology; Proteomics

Indexed keywords

ALKYLATING AGENT; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; ASPARAGINASE; CELL PROTEIN; DNA; DNA TOPOISOMERASE INHIBITOR; GYRASE INHIBITOR; PLATINUM DERIVATIVE; RNA; SILANE DERIVATIVE; TUMOR MARKER;

ANALYTIC METHOD; BIOINFORMATICS; BREAST CANCER; CANCER CELL CULTURE; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; COMPUTER PROGRAM; DATA ANALYSIS; DNA DETERMINATION; DNA MICROARRAY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; EXPERIMENTATION; FUNCTIONAL ASSESSMENT; GENE TECHNOLOGY; GENETIC MARKER; GENETIC TRANSCRIPTION; GENOME ANALYSIS; HUMAN; MOLECULAR BIOLOGY; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; RNA ANALYSIS; TREATMENT PLANNING;

EID: 8444248220     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: 10.3233/BD-2004-19103     Document Type: Review

References (58)

1. J.N. Weinstein, Omic and hypothesis-driven research in the molecular pharmacology of cancer, Curr. Opinion in Pharmacology 2 (2002), 361-365.
2. J.N.Weinstein, Fishing Expeditions, Science 282 (1998), 627-628.
3. J.N. Weinstein and Y. Pommier, Transcriptomic analysis of the NCI-60 cancer cell lines, Biol 326 (2003), 909-992.
4. J.N.Weinstein, Linking drugs and genes: Pharmacogenomics, pharmacoproteomics, bioinformatics, and the NCI-60, in: Oncogenomics: Molecular approaches to cancer, C. Brenner and D.J. Duggan, eds, in press, John Wiley, Inc.: New York.
5. M.R. Emmert-Buck et al., Laser capture microdissection, Science 274(5289) (1996), 998-1001.
6. A. Koutsoukos et al., Discrimination techniques applied to the NCI in vivo antitumor drug screen: Predicting biochemical mechanism of action, Statistics in medicine 13 (1994), 719-730.
7. L.M. Shi et al., Mining and visualizing large anticancer drug discovery databases, J. Chem. Inf. Comput. Sci. 40 (2000), 367-379.
8. O. Keskin et al., Characterization of anticancer agents by their growth inhibitory activity and relationships to mechanism of action and structure, Anticancer Drug Des 15 (2000), 79-98.
9. M.R. Boyd, The future of new drug development, in: Current Therapy in Oncology, J.E. Neiderhuber, ed., Decker: Philadelphia, 1992, 11-22.
10. K.D. Paull et al., Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of mean graph and COMPARE algorithm, J. Natl. Cancer Inst. 81 (1989), 1088-1092.
11. M. Gupta, A. Fujimori and Y. Pommier, DNA topoisomerase, I. Biochim. Biophys. Acta 1262 (1995), 1-14.
12. F. Leteurtre et al., Azatoxin derivatives with potent and selective action on topoisomerase II, Biochem. Pharmacol. 49 (1995), 1283-1290.
13. F. Leteurtre et al., Topoisomerase II inhibition by anthrapyrazoles, DuP 937&DuP 941 (Losoxanthrone) and cytotoxicity in the NCI cell screen, J. Natl. Cancer Inst. 86 (1994), 1239-1244.
14. E. Solary et al., Dual inhibition of topoisomerase II and tubulin polymerization by azatoxin, a novel cytotoxic agent, Biochem. Pharmacol. 45 (1993), 2449-2456.
15. H.-M. Koo et al., Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes, J. Natl. Cancer Inst. 56 (1996), 5211-5216.
16. G. Kohlhagen et al., Protein-linked DNA strand breaks induced by NSC 314622, a non-camptothecin topoisomerase I poison, Mol. Pharmacol. 54 (1998), 50-58.
17. E.S. Cleaveland et al., Site of action of two novel pyrimidine biosynthesis inhibitors accurately predicted by the compare program, Biochem. Pharmacol. 49 (1995), 947-954.
18. J.M. Freije et al., Identification of compounds with preferential inhibitory activity against low-Nm23-expressing human breast carcinoma and melanoma cell lines, Nature Med 3 (1997), 395-401.
19. R. Bai et al., Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data, J. Biol. Chem. 266 (1991), 15882-15889.
20. E. Hamel et al., Antitumor 2,3-dihydro-2-(aryl)-4(1H)-quinazolinone derivatives, Interactions with tubulin. Biochem. Pharmacol. 51(1) (1996), 53-59.
21. S.C. Kuo et al., Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4′-substituted phenyl)-4-quinolones and related compounds: Identification as antimitotic agents interacting with tubulin, J. Med. Chem. 36 (1993), 1146-1156.
22. K.D. Paull et al., Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluation of differential cytotoxicity data, Cancer Res 52 (1992), 3892-3900.
23. K. Wosikowski et al., Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns, J. Natl. Cancer Inst. 89 (1997), 1505-1513.
24. J.N. Weinstein et al., Neural computing in cancer drug development: predicting mechanism of action, Science 258(5081) (1992), 447-451.
25. W.W. van Osdol et al., Use of the Kohonen self-organizing map to study the mechanisms of action of chemotherapeutic agents, J. Natl. Cancer Inst. 86 (1994), 1853-1859.
26. W.W. van Osdol, T.G. Myers and J.N. Weinstein, Neural network techniques for the informatics of cancer drug discovery, Methods in Enzymology 321 (2000), 369-395.
27. J.N. Weinstein et al., Predictive statistics and artificial intelligence in the US National Cancer Institute's drug discovery program for cancer and AIDS, Stem Cells 12 (1994), 13-22.
28. J.N. Weinstein et al., An information-intensive approach to the molecular pharmacology of cancer, Science 275 (1997), 343-349.
29. Y. Fan et al., Quantitative structure-antitumor activity relationships of camptothecins: Cluster analysis and genetic algorithm-based studies, J. Med. Chem. 44 (2001), 3254-3263.
30. L.M. Shi et al., Mining the NCI anticancer drug discovery databases: Genetic function approximation for the QSAR study of anticancer ellipticine analogues, J. Chem. Inf. Comput. Sci. 38 (1998), 189-199.
31. L.M. Shi et al., Mining the anticancer activity database generated by the US National Cancer Institute's drug discovery program using statistical and artificial intelligence techniques, J. Chem. Inf. Comput. Sci. (1998).
32. L.M. Shi et al., Mining the National Cancer Institute Anticancer Drug Discovery Database: Cluster analysis of ellipticine analogs with p53-inverse and central nervous system-selective patterns of activity, Mol. Pharmacol. 53 (1998), 241-251.
33. A.A. Rabow et al., Mining the National Cancer Institute's tumor-screening database: Identification of compounds with similar cellular activities, J. Med. Chem. 45 (2002), 818-840.
34. D. Rogers and A.J. Hopfinger, Application of genetic function approximation to quantitative structure-activity relationships and quantitative structure-property relationships, J. Chem. Inf. Comput. Sci. 34(4) (1994), 854-866.
35. G.W.A. Milne et al., National Cancer Institute drug information system 3D database, J. Chem. Inf. Comput. Sci. 34(5) (1994), 1219-1224.
36. M. Alvarez et al., Generation of a drug resistance profile by quantitation of MDR-1/P-glycoprotein expression in the cell lines of the NCI anticancer drug screen, J. Clin. Investig. 95 (1995), 2205-2214.
37. M.A. Izquierdo et al., Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines, Int. J. Cancer 65 (1996), 230-237.
38. J-S. Lee et al., Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen, Molec. Pharmacol. 46 (1994), 627-638.
39. L.Wu et al., Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening, Cancer Res 52 (1992), 3029-3034.
40. K.-V. Chin, I. Pastan and M.M. Gottesman, Function and regulation of the human multidrug resistance gene, Adv Cancer Research 60 (1993), 157-180.
41. M.M. Gottesman and I. Pastan, Biochemistry of multidrug resistance mediated by the multidrug transporter, Annu. Rev. Biochem. 62 (1993), 385-427.
42. P.M. O'Connor et al., Characterization of the p53-tumor suppressor pathway in cells of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents, Cancer Research 57 (1997 , 4285-4300.
43. T.G. Myers et al., A protein expression database for the molecular pharmacology of cancer, Electrophoresis 18 (1997), 647-653.
44. G. Li et al., Rapid protein identification from two-dimensional polyacrylamide gels by MALDI mass spectrometry, Electrophoresis 18 (1997), 647-653.
45. C.P. Paweletz et al., Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front, Oncogene 20 (2001), 1981-1989.
46. S. Nishizuka et al., Diagnostic markers that distinguish colon and ovarian adenocarcinomas: Identification by genomic, proteomic, and tissue array profiling, Cancer Res 63(17) (2003), 5243-5250.
47. S. Nishizuka et al., Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysete microarrays, Proc Natl Acad Sci USA 100(24) (2003), 14229-14234.
48. D.T. Ross et al., Systematic variation in gene expression patterns in human cancer cell lines, Nature Genetics 24 (2000), 227-235.
49. U. Scherf et al., A gene expression database for the molecular pharmacology of cancer, Nature Genetics 24 (2000), 236-244.
50. J.E. Staunton et al., Chemosensitivity prediction by transcriptional profiling, Proc. Natl. Acad. Sci. USA. 98 (2001), 10787-10792.
51. D. Shalon, S.J. Smith and P.O. Brown, A DNA microarray system for analyzing complex DNA samples using two- color fluorescent probe hybridization, Genome Res 6(7) (1996), 639-645.
52. J.K. Lee et al., Comparing cDNA and oligonucleotide array data: Concordance of gene expression across platforms for the NCI-60 cancer cell lines, Genome Biol 4(12) (2003), R82.
53. A.V. Roschke et al., Karyotypic complexity of the NCI-60 drug-screening panel, Cancer Research 63(24) (2003), 8634-8647.
54. W.C. Reinhold et al., Apoptotic susceptibility of cancer cells selected for camptothecin resistance: Gene expression profiling, functional analysis, and molecular interaction mapping, Cancer Res 63 (2003), 1000-1011.
55. T.G. Myers et al., An information intensive strategy for drug discovery in cancer and AIDS: Relating cell cycle factors to patterns of drug activity, Proc. Am. Assoc. Cancer Res. 36 (1995), 305.
56. L. Tanabe et al., MedMiner: An internet tool for mining information, with application to gene expression profiling, BioTechniques 27 (1999), 1210-1217.
57. K.J. Bussey et al., MatchMiner: A tool for batch navigation among gene and gene product identifiers, Genome Biology 4(4) (2003), R27.
58. B. Zeeberg et al., GoMiner: A resource for biological interpretation of genomic and proteomic data, Genome Biology 4(4) (2003), R28.